A Long-Term Study in China on Metabolic Associated Fatty Liver Disease and Fatty Liver Conditions to Understand Risks and Outcomes

What this Trial Is About

This research aims to better understand metabolic dysfunction-associated fatty liver disease MAFLD, a condition defined by fatty liver with metabolic risks like obesity, diabetes, or metabolic problems. The study also seeks to compare MAFLD with non-alcoholic fatty liver disease NAFLD, including patients who have liver fat but no metabolic risk, and those with both MAFLD and other liver diseases. The goal is to clarify clinical features and improve diagnosis and outcomes for these patients. The study includes two parts first, a cross-sectional analysis collecting clinical data from patients with fatty liver to examine their characteristics second, a long-term follow-up involving collection of plasma, urine, and stool samples to identify biomarkers that help predict disease progression and patient stratification. The trial will observe patients over time to assess these factors. Participants will undergo clinical data collection and sample provision, with researchers monitoring for outcomes such as all-cause death over 10 years. They will also track liver-related complications and other important health issues like cardiovascular disease. The study aims to understand how different metabolic factors relate to disease progression. This long-term observational approach will provide insights to inform better management of MAFLD and NAFLD.

A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China